We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

35 hedge funds and large institutions have $15.5M invested in AIM ImmunoTech in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

0% more funds holding

Funds holding: 35 → 35 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

8% less capital invested

Capital invested by funds: $16.8M → $15.5M (-$1.36M)

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
5
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$344K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$298K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$143K
4
WG
Winton Group
United Kingdom
+$118K
5
RJFSA
Raymond James Financial Services Advisors
Florida
+$103K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$699K
2
BlackRock
BlackRock
New York
-$335K
3
Citadel Advisors
Citadel Advisors
Florida
-$234K
4
GCP
GSA Capital Partners
United Kingdom
-$170K
5
VF
Virtu Financial
New York
-$67K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$5.39M +$3K +14 +0.1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.29M +$143K +668 +3%
BlackRock
3
BlackRock
New York
$1.77M -$335K -1,565 -16%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$756K – – –
BCM
5
Bridgeway Capital Management
Texas
$529K -$53.8K -251 -9%
State Street
6
State Street
Massachusetts
$345K +$344K +1,606 New
Renaissance Technologies
7
Renaissance Technologies
New York
$329K -$699K -3,262 -68%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$299K +$298K +1,393 New
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$251K – – –
Verition Fund Management
10
Verition Fund Management
Connecticut
$232K – – –
Northern Trust
11
Northern Trust
Illinois
$188K +$41.8K +195 +29%
HighTower Advisors
12
HighTower Advisors
Illinois
$144K +$8.57K +40 +6%
WG
13
Winton Group
United Kingdom
$118K +$118K +549 New
RJFSA
14
Raymond James Financial Services Advisors
Florida
$103K +$103K +480 New
Cambridge Investment Research Advisors
15
Cambridge Investment Research Advisors
Iowa
$100K – – –
SWM
16
SeaCrest Wealth Management
New York
$94K – – –
Rockefeller Capital Management
17
Rockefeller Capital Management
New York
$86K – – –
XT
18
XTX Topco
Cayman Islands
$63K +$62.8K +293 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$54K – – –
SSA
20
Schonfeld Strategic Advisors
New York
$49K -$33K -154 -40%
Charles Schwab
21
Charles Schwab
California
$44K – – –
CAPTRUST Financial Advisors
22
CAPTRUST Financial Advisors
North Carolina
$43K +$12.9K +60 +43%
LPL Financial
23
LPL Financial
California
$37K +$1.07K +5 +3%
Bank of America
24
Bank of America
North Carolina
$32K -$214 -1 -0.7%
CB
25
Community Bank
New York
$28K – – –
1
2

AIM Hedge Fund Activity: Q2 2021 in Review

35 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2021, worth a combined $15.5M — down 8.1% from $16.8M a quarter earlier.

Fund positioning in AIM was balanced in Q2 2021: 9 funds opened new positions, 9 closed out, 8 added to existing stakes and 5 trimmed.

The largest buyer was State Street, opening a new position worth an estimated $344K. The largest seller was Renaissance Technologies, cutting an estimated $699K.

  • 35 institutional investors held AIM ImmunoTech (AIM) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $15.5M of AIM ImmunoTech stock for Q2 2021, down 8.1% quarter-over-quarter.
  • 9 funds opened new AIM ImmunoTech positions in Q2 2021 and 9 closed out, a net change of 0 holders.
  • The largest AIM ImmunoTech buyer in Q2 2021 was State Street, an estimated $344K added.
  • The largest AIM ImmunoTech seller in Q2 2021 was Renaissance Technologies, an estimated $699K sold.

Based on aggregated 13F filings for Q2 2021.